The T-DOT (Toronto Disparities, Overdose and Treatment) study is an ongoing prospective cohort of people who use drugs in Toronto that was started in 2018 (formerly OiSIS). T-DOT aims to evaluate harm reduction hubs, including supervised consumption sites (SCS), drug checking services, opioid agonist therapies (OAT) and the broader continuum of care for substance related issues on participant health, behavioural and social outcomes.
The CDPE is leading a study to evaluate the impact of safer opioid supply programs in Toronto, Ontario.
The Policy Impact Unit works in partnership with drug policy stakeholders – including people who use drugs, affected communities, civil society, and policymakers – to support the development of evidence- and rights-based drug policies in Canada and around the globe.
The CDPE is thrilled to announce that we will be hosting Steffanie Strathdee, PhD, a global leader in substance use epidemiology and disease prevention, as the Arthur S. Slutsky Scholar-in-Residence at St. Michael’s Hospital for the next year. Dr. Strathdee, named one of TIME Magazine’s 50 most important people in health care, brings decades of expertise in infectious disease epidemiology and community driven research initiatives, and we are delighted to have her enrich our team and the St. Michael’s Hospital research community! Dr. Strathdee is the founder and Co-Director of the Centre for Innovative Phage Applications and Therapeutics (IPATH) and a Professor of Medicine at UC San Diego. She is recognized for her research on HIV in marginalized populations and for helping revive phage therapy after using it to save her husband from a deadly superbug infection. We are very lucky to have the opportunity to work alongside such an influential scientist, welcome Dr. Strathdee to the CDPE team! 😊